Frontiers in Immunology Submission Guide (2026)

Most current Frontiers in Immunology submission pages summarize broad Frontiers mechanics: choose an article type, select a specialty section, follow author guidelines, and complete open-access submission. That helps with portal compliance, but it misses the section-level editorial decision.

This guide gives you the decision layer beyond official publisher instructions. Frontiers itself makes authors choose a specialty section and only offers article types available for that section. The practical screen is whether the abstract, contribution statement, methods, cohort table, section selection, and data availability language make the immunology relevance and section fit obvious before collaborative review starts.

Evidence basis and source limitations: this page uses public Frontiers guidance and Manusights pre-submission patterns; it is not a private live Frontiers submission-session test. Official publisher instructions cannot tell whether the selected specialty section, cohort table, methods, and contribution statement will satisfy the section editor. What editors actually screen for is section-level fit before collaborative review.

If you want the quick pre-upload call, run a Frontiers in Immunology manuscript fit check before opening the Frontiers submission platform.

Submit if your paper fits these criteria: clinical immunology with patient data, systematic reviews with rigorous methodology, or translational research connecting bench findings to clinical outcomes. Selectivity varies materially by specialty section, so section choice matters almost as much as paper quality.

Don't submit basic mechanistic studies without clinical context. The journal prioritizes translational impact over novel molecular mechanisms. If your paper describes a new pathway but doesn't connect to disease or therapy, consider Journal of Immunology instead.

The collaborative review model means constructive feedback, but editors filter aggressively for scope fit. Check the journal's positioning, section mix, and recent publications before deciding whether it aligns with your goals.

Source: Frontiers in Immunology Author Guidelines, Article Types, JCR 2024, accessed May 2026.

Frontiers in Immunology editorial workflow at the Frontiers submission platform (Frontiersin submission portal) runs on Frontiers' published fast-cadence collaborative review model. Editors screen for translational / clinical relevance, specialty-section fit, and methodological rigor in the first read.

Day 1-3: Receipt and tech-check

The Frontiers platform confirms file integrity, the 200-word scope-and-relevance statement, the 5-8 keywords, the specialty-section assignment, ORCID for corresponding author, the COI declaration, and the AI-use disclosure. Section-eligible article types are confirmed (some sections accept only some article types).

Day 3-10: Specialty-section editor assignment

A specialty-section editor (e.g., Clinical Immunology, Cancer Immunology, Autoimmunity, Inflammation) takes the paper. The scope read decides whether the contribution is broad-Frontiers-in-Immunology work or better routed to Frontiers in Cell and Developmental Biology, Frontiers in Oncology, Frontiers in Medicine, or specialty venues (J. Immunol., Cancer Immunol. Res., Nature Immunology).

Week 2-4: Editorial scope assessment

The section editor decides desk-reject, transfer-offer to a different Frontiers journal, or send for collaborative review. Section selectivity varies: Clinical Immunology + Cancer Immunology + Inflammation are the most selective; broader sections are more permissive.

Week 4-8: Collaborative peer review

Frontiers' open collaborative review model means reviewer + author + editor identities are transparent. 2 reviewers report typically. Authors and reviewers iterate to consensus (or impasse).

Week 10-14: First decision

Accept / decline. Frontiers does not use the traditional major-revision verdict; consensus or rejection emerges from collaborative dialogue. Median time to first decision is 12-14 weeks.

Editors screen Frontiers in Immunology uploads against the following artifacts at the Frontiers platform tech-check (Frontiersin submission portal). Missing any of the first five triggers a technical-return rather than substantive desk review.

The required artifacts are:

• the cover letter (with translational / clinical-relevance framing and any prior-rejection / preprint disclosure)

• the manuscript file in the Frontiers Word or LaTeX template

• the 200-word scope-and-relevance statement at submission

• the 5-8 keywords

• the specialty-section assignment (load-bearing)

• ORCID for the corresponding author (required)

• the author contributions statement

• the conflicts of interest declaration

• the funding statement and source listing

• the data availability statement (FAIR principles encouraged, public repositories preferred)

• the ethics approval and consent statement (IRB / IACUC for human / animal work)

• the AI-use disclosure

• the supplementary information (extended methods, additional figures, datasets)

• the suggested reviewers (Frontiers does not require these

section editors assign reviewers).

Frontiers in Immunology operates through 20+ specialty sections, each with distinct editorial preferences and practical selectivity levels. You don't just submit to "Frontiers in Immunology." You submit to Clinical Immunology, Cancer Immunology, Autoimmunity, or another specific section.

• Most competitive sections:

• Clinical Immunology (focuses on patient studies, biomarkers, therapeutic trials)

• Inflammation (requires strong mechanistic data with clinical relevance)

• Immunological Memory (prefers longitudinal studies or vaccine research)

• More accessible sections:

• Autoimmunity (accepts case series and observational studies)

• Vaccines and Molecular Therapeutics (welcomes early-phase development work)

• Nutritional Immunology (emerging field with fewer submissions)

Choose your section carefully. The same paper submitted to Clinical Immunology might get desk rejected, while the identical study could get accepted in Autoimmunity. Each section has different editors, different reviewer pools, and different standards for clinical impact.

• Section selection strategy:

Read the last 6 months of papers in your target section. Match the study design, sample size, and clinical context. If most papers in Clinical Immunology have 200+ patients and yours has 45, consider Autoimmunity instead.

The specialty section editors communicate with each other. If you submit to the wrong section, they'll transfer your paper rather than reject it. But transfers add 2-3 weeks to the process, and the receiving section might have different standards.

Cancer Immunology gets the most submissions but accepts systematic reviews more readily than original research. If you have a meta-analysis of immunotherapy trials, start there. For basic T-cell biology without cancer context, try Immunological Tolerance and Regulation.

The section structure matters more at Frontiers than at traditional journals. Nature Immunology editors handle scope decisions centrally. At Frontiers, the specialty section editor makes the initial call. Pick the right section, and you're talking to someone who understands your specific research area.

This update spot-checked recent Frontiers in Immunology section records to keep the guidance grounded in the current article mix, including DOI examples 10.3389/fimmu.2026.1740184, 10.3389/fimmu.2026.1756560, and 10.3389/fimmu.2026.1764990.

The submission portal requires ORCID registration for all authors before you can start. Don't begin formatting your manuscript until every co-author has an ORCID ID. The system won't let you proceed without them.

• Required documents:

• Cover letter (specific template requirements)

• Manuscript file (LaTeX or Word)

• Figure files (minimum 300 DPI, maximum 10MB each)

• Data availability statement

• Competing interests declaration

• Ethics statements (IRB approval numbers, patient consent documentation)

• Formatting specifics:

Word limit varies by article type. Original Research allows 12,000 words including references. Reviews can go up to 15,000 words. Methods articles are capped at 8,000 words. The portal counts words automatically and will block submission if you exceed limits.

Figures can be embedded in the manuscript file during initial submission. If accepted, you'll need to provide high-resolution separate files. The journal accepts color figures without additional fees, unlike many traditional publishers.

The cover letter template is specific. You need: research question, methodology summary, key findings, clinical relevance statement, and suggested reviewers. Use these cover letter examples as templates, but customize for Frontiers' collaborative review philosophy.

• Submission checklist:

• All authors have ORCID IDs

• Specialty section selected

• Word count within limits

• Ethics approvals documented

• Data sharing plan included

• Competing interests declared

• Three suggested reviewers provided

The portal saves your progress automatically. You can submit in multiple sessions. But once you hit "submit," you can't modify anything. Triple-check your specialty section choice before final submission.

Average time to first decision is 80 days, but this varies by specialty section and manuscript complexity. Systematic reviews take longer than original research. Clinical trials with patient data get expedited review.

• Timeline breakdown:

• Editorial screening: 7-14 days

• Reviewer recruitment: 14-21 days

• Peer review period: 30-45 days

• Editorial decision: 7-10 days

The collaborative review model encourages reviewers to see each other's comments and build consensus. You'll get more constructive feedback than adversarial criticism. Reviewers know their comments are shared, which tends to make reviews more professional and helpful.

• During review:

You can track progress through the submission portal. Status changes from "Under Review" to "Required Reviews Completed" to "Editor Decision Started." Don't contact the editorial office unless the process exceeds 90 days.

If reviewers request major revisions, you get 60 days to respond. Minor revisions have a 30-day deadline. The system sends automatic reminders as deadlines approach.

• Revision strategy:

Address every reviewer comment specifically. The collaborative model means reviewers will see your response and judge whether you've addressed their concerns adequately. Don't dismiss any feedback, even if you disagree.

The biggest mistake is assuming Frontiers has lower standards because the journal publishes at scale. The broader scope changes throughput, but editors still filter hard for translational relevance, section fit, and methodological credibility.

• Top rejection triggers:

1. Poor clinical context - Describing molecular mechanisms without connecting to disease or therapy

1. Weak systematic review methodology - Missing PROSPERO registration, inadequate search strategies, no quality assessment

1. Wrong specialty section - Submitting autoimmunity research to Clinical Immunology section

Authors often submit basic immunology papers because they think Frontiers will accept anything. The journal wants translational relevance, not just novel biology. If your T-cell study doesn't connect to autoimmune disease, cancer, or vaccines, try a basic immunology journal instead.

Systematic reviews fail when methodology is sloppy. Register your protocol with PROSPERO before starting. Use multiple databases for literature searches. Include quality assessment tools like Newcastle-Ottawa or Cochrane risk-of-bias. The journal publishes many systematic reviews, but only rigorous ones.

• Original Research (60% of publications): Clinical studies, translational research, biomarker validation. Basic mechanistic studies need strong clinical relevance. Sample sizes matter less than study design quality.

• Reviews (25% of publications): Systematic reviews and meta-analyses perform better than narrative reviews. PRISMA compliance is mandatory. Expert opinion pieces rarely get accepted unless from recognized thought leaders.

• Clinical Trial (10% of publications): Phase I-III trials, real-world effectiveness studies, post-market surveillance data. Requires trial registration and follows CONSORT guidelines.

• Methods (5% of publications): New techniques, protocols, or analytical approaches. Must demonstrate advantage over existing methods with validation data.

Success varies by article type and section. Systematic reviews often perform better when methodology is strong, while original research and clinical trial papers face more direct scrutiny on section fit, ethical handling, and translational value.

Position your work appropriately. Don't submit a narrative review when you could do a systematic review. Don't call a case series "original research" when it belongs in Clinical Trial category.

Compare options based on your career stage and research type. Consider these factors when choosing journals alongside Frontiers' specific strengths and limitations.

• Choose Nature Immunology if: Your basic research has broad immunological significance, you have strong mechanistic data, and you can wait 6+ months for review.

• Choose Immunity if: You're reporting paradigm-shifting findings, have comprehensive experimental validation, and prioritize prestige over publication speed.

• Choose Journal of Immunology if: Your work is solid basic immunology without clinical connection, you prefer traditional peer review, and you want faster publication than Nature journals.

• Choose Clinical Immunology if: Your research focuses specifically on clinical applications, you have patient data, and you want a specialized audience over broad readership.

Frontiers works best for translational research that connects basic findings to clinical relevance. If your paper sits between basic and clinical research, Frontiers offers a good middle ground with reasonable review times and constructive feedback.

The collaborative review model suits early-career researchers who benefit from detailed, educational feedback. Senior researchers who prefer traditional anonymous review might find other journals more comfortable.

Before you upload, run your manuscript through a Frontiers in Immunology submission readiness check to catch the issues editors filter for on first read.

For manuscripts targeting Frontiers in Immunology, five patterns generate the most consistent desk rejections worth knowing before submission.

According to Frontiers in Immunology submission guidelines, each pattern below represents a documented desk-rejection trigger; per SciRev data and Clarivate JCR 2024 benchmarks, addressing these before submission meaningfully reduces early-rejection risk.

Basic immunology paper without a clinical or translational anchor

The Frontiers in Immunology author guidelines position the journal as publishing immunology research with translational or clinical relevance, and the collaborative review process is designed to evaluate manuscripts where the disease or therapeutic connection is visible from submission. Manusights pre-submission pattern analysis shows many desk rejections involve manuscripts that describe novel molecular pathways or immune cell biology without connecting the findings to disease, therapy, or patient outcomes.

Editors specifically screen for manuscripts where the clinical or translational consequence is present in the framing, not implied from the mechanism alone.

Systematic review submitted without PROSPERO registration

The same pattern analysis often finds many systematic review and meta-analysis submissions arrive without a registered protocol in PROSPERO or an equivalent prospective registration, or with search strategies and quality assessment tools missing from the supplementary materials. In practice, editors consistently reject systematic reviews where the methodology documentation is incomplete at submission, because the journal's standards for evidence synthesis treat pre-registration and transparent search reporting as submission requirements rather than revision-stage corrections.

Specialty section choice misaligned with the immunology paper

A related pattern is that many submissions are routed to a specialty section whose editorial standards and reviewer pool do not match the manuscript's study design, patient population, or research question. Editors explicitly consider whether the specialty section fits the manuscript before accepting for review, because section-level selectivity at Frontiers is materially different from overall journal-level selectivity.

Check specialty section choice misaligned with the immunology paper before submitting to Frontiers in Immunology →

Clinical study too small for the target specialty section's bar

A related pattern is that many submissions to competitive sections such as Clinical Immunology arrive with patient cohort sizes that fall well below the sample sizes that section editors and reviewers expect for the clinical claims being made. In our analysis of submission difficulties at Frontiers in Immunology, this pattern is most common in submissions where the section was chosen for topic fit without checking the typical study scale in that section's recent publications.

Check clinical study too small for the target specialty section's bar before submitting to Frontiers in Immunology →

Cover letter explains the science but not the clinical consequence

A related pattern is that many submissions arrive with cover letters that describe the immunological mechanisms studied without stating what the findings mean for patient care, drug development, or clinical decision-making. Editors explicitly consider whether the cover letter makes the translational case before routing the paper for collaborative review.

SciRev author-reported review times and Clarivate JCR 2024 bibliometric data provide additional benchmarks when planning your submission timeline.

Before submitting to Frontiers in Immunology, a Frontiers in Immunology submission readiness check identifies whether your translational framing, systematic methodology, and section choice meet the editorial bar before you commit to the submission.

Or see example reports before you finalize.

Check cover letter explains the science but not the clinical consequence before submitting to Frontiers in Immunology →

• Is Frontiers in Immunology a Good Journal? An Honest Assessment for 2026 - Use a fuller journal-evaluation page before deciding whether the fit is right

• Is Frontiers in Immunology a Good Journal? An Honest Assessment for 2026 - Reputation analysis and career considerations

• Journal Cover Letter Template: 5 Filled-In Examples for Any Journal - Cover letter templates and examples

Getting your manuscript ready for submission? Manusights provides detailed pre-submission reviews to catch formatting issues, scope mismatches, and editorial red flags before you submit.

If your manuscript is already in the portal, use the Frontiers in Immunology Under Review status guide to interpret the current status before sending a follow-up email.